Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466569 · ClinicalTrials.gov registry record · Phase 1
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by AbGenomics B.V Taiwan Branch.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01466569 is a Phase 1 study that has completed, run by AbGenomics B.V Taiwan Branch. The registered enrollment target is 13 participants.
The verdict
NCT01466569, a Phase 1 study, has completed, sponsored by AbGenomics B.V Taiwan Branch.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability profile including the dose limiting toxicity of AbGn-7 in patients with chemo-refractory advanced solid tumor of epithelial origin, and of AbGn-7 in combination with FOLFOX7 in patients with chemo-naive/chemo-refractory recurrent, locally advanced or metastatic gastric cancer.
Interventions
- DRUG AbGn-7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01466569
The ClinicalTrials.gov registry entry for NCT01466569 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbGenomics B.V Taiwan Branch, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AbGn-7 is the first listed.
NCT01466569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01466569 about?
NCT01466569 is a clinical study titled "An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors". The purpose of this study is to determine the safety and tolerability profile including the dose limiting toxicity of AbGn-7 in patients with chemo-refractory advanced solid tumor of epithelial origin, and of AbGn-7 in combination with FOLFOX7 in patients with chemo-naive/chemo-refractory recurrent,...
What is the current status of trial NCT01466569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2011-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01466569?
The interventions under investigation include: AbGn-7 (DRUG).
Who is sponsoring clinical trial NCT01466569?
This trial is sponsored by AbGenomics B.V Taiwan Branch, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.